Abdominoscrotal Lymphangioma Masquerading as a Communicating Hydrocele: A Case Report.

A 5-year old boy presented with a picture of communicating hydrocele and was discovered to have an abdominoscrotal lymphangioma after undergoing hydrocele surgery. Upon initial presentation the lymphangioma was missed and the child underwent inguinal approach surgery for hydrocele. The lymphangioma was then noticed as an abdominal lump due to a rapid increase in size within 1 week following the hydrocele surgery. The sudden enlargement of the lymphangioma was due to intra-cystic hemorrhage post-operatively. The lymphangioma was then completely excised with no recurrence noted after 1 year of follow up. This is a rare case of a retroperitoneal, abdominoscrotal lymphangioma masquerading as a communicating hydrocele. Keywords: Communicating Hydrocele, Abdominoscrotal lymphangioma, Scrotal Swelling.

Shorter anogenital distance correlates with the severity of hypospadias in pre-pubertal boys.

STUDY QUESTION: Do pre-pubertal boys with hypospadias have a shorter anogenital distance (AGD) than boys with normal genitalia? SUMMARY ANSWER: AGD is significantly shorter in boys with hypospadias and decreases with the severity of hypospadias. WHAT IS KNOWN ALREADY: Animal studies have shown that androgen disruption and exposure to endocrine disrupting chemicals during a critical time period in early gestation, termed the male programming window (MPW), result in hypospadias and reduced AGD; and the severity of hypospadias correlates with the reduction in AGD. However, this correlation has not been established in humans. STUDY DESIGN, SIZE, DURATION: A prospective descriptive study involving measurement of AGD in pre-pubertal boys (n = 458) presenting to our pediatric urology clinic with hypospadias and normal genitalia was performed over a period of 3 years. PARTICIPANTS/MATERIALS, SETTING, METHODS: AGD was measured in pre-pubertal boys from 5 months to 14 years of age presenting to our clinic with hypospadias (n = 180: four were excluded) and compared with randomly selected boys with normal genitalia (controls, n = 274). Three variants of AGD, from the midpoint of the anus to base of the scrotum (AGD-AS), to the anterior base of penis (AGD-1) and to the posterior base of penis (AGD-2), were measured and assessed for correlation with the severity of hypospadias. Severity of hypospadias was classified as anterior, middle and posterior according to the meatal location. MAIN RESULTS AND THE ROLE OF CHANCE: No significant difference in weight (P = 0.123), age (P = 0.162) or height (P = 0.591) between the two groups was observed. Only AGD-AS was significantly shorter in boys with hypospadias compared with controls (mean ± SD: 40.6 ± 9.7 mm versus 45.6 ± 9.4 mm, P < 0.001). This relation persisted after adjusting AGD for weight, height and age (ß = 0.016, 95% confidence interval: 0.10-0.21; P < 0.001). The Spearman test showed a significant negative correlation for the severity of hypospadias with all the three AGD measures. Analysis of variance between anterior, middle and posterior subgroups showed a significant reduction in mean AGD-AS (P = 0.003) and AGD-2 (P = 0.008). LIMITATIONS, REASONS FOR CAUTION: No data were collected pertaining to in utero exposure to endocrine disrupting chemicals (EDCs) or cigarette smoke, or current diet and environmental exposure to EDCs, which may have influenced the AGD. Family history of genital malformation and use of IVF were not known. There may have been a selection bias as only boys presenting to our clinic were included. WIDER IMPLICATIONS OF THE FINDINGS: The findings suggest that prenatal androgens during early gestation influence development of the male reproductive system and support the existence of a MPW in humans. Of the three AGDs, AGD-AS may be the most reliable biomarker of this in utero androgen action. However, no direct link to any specific exposure leading to shortened AGD in pre-pubertal boys with hypospadias could be determined. Further large scale multi-center studies are needed to understand this association better. STUDY FUNDING/COMPETING INTERESTS: Funding was from the Hypospadias Foundation. No conflicts of interest to disclose.

Can Aliskiren be Considered as a New Novel Drug for Hypertension?

Hypertension is one of the most common causes of death across the globe. Many trials and drugs have been used for controlling the debilitating effects of hypertension. One such new class of drug is direct renin inhibitors (DRI), e.g., aliskiren, which block the renin-angiotensin system (RAS). It blocks the very first step in the RAS system. Multiple trials have been carried out debating the outcome of monotherapy and combination therapy with other classes of hypertensive drugs. Focus on compliance, adverse effects, and the cost have also been in the news. Extensive studies are still needed to justify the clinical use of a DRI in the effective treatment of hypertension.

Recent Advances and Review on Treatment of Stiff Person Syndrome in Adults and Pediatric Patients.

Stiff Person Syndrome (SPS) is one of the rarest autoimmune neurological disorders, which is mostly reported in women. It is characterised by fluctuating muscle rigidity and spasms. There are many variants of SPS, these include the classical SPS, Stiff Leg Syndrome (SLS), paraneoplastic variant, gait ataxia, dysarthria, and abnormal eye movements. Studies have shown that the paraneoplastic variant of SPS is more common in patients with breast cancer who harbour amphiphysin antibodies, followed by colon cancer, lung cancer, Hodgkin's disease, and malignant thymoma.  Currently, the treatment for SPS revolves around improving the quality of life by reducing the symptoms as far as possible with the use of GABAergic agonists, such as diazepam or other benzodiazepines, steroids, plasmapheresis, and intravenous immunoglobulin (IVIG). There have been random clinical trials with Rituximab, but nothing concrete has been suggested. A treatment approach with standard drugs and cognitive behavioral therapy (CBT) seems to be promising.

Isotonic riboflavin and HPMC with accelerated cross-linking protocol.

PURPOSE: The aim of this study was to monitor corneal pachymetry changes during accelerated collagen cross-linking (CXL) for keratoconus while using isotonic riboflavin with HPMC. METHODS: All consecutive patients who underwent CXL for progressive keratoconus, using accelerated protocol and isotonic riboflavin with HPMC, from December 2012 to September 2013 were included in the study. The corneal pachymetry measurements were obtained at different time points: after epithelial removal, after riboflavin application for 20 minutes, and after ultraviolet A irradiation for 10 minutes at 9 mW/cm. RESULTS: A total of 14 eyes of 14 consecutive patients were included in this study. The mean age of the patients was 19 ± 8 years. There were 8 left eyes and 6 right eyes. After epithelial debridement, the thinnest pachymetric readings were between 324 and 452 µm (average, 401.4 ± 40.7 µm). No significant difference (P = 0.80) was found between the deepithelialized corneal thickness and after 20 minutes of isotonic riboflavin with HPMC (pachymetric average, 405.3 ± 37.5 µm). Pachymetric average after ultraviolet A irradiation was 419.29 ± 20.60 µm. There was no statistical significant change in the corneal thickness after the irradiation (P = 0.24). CONCLUSIONS: During corneal CXL using isotonic riboflavin and HPMC with accelerated cross-linking protocol, no significant decline in the corneal thickness was demonstrated.